ATE444286T1 - 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung - Google Patents

2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung

Info

Publication number
ATE444286T1
ATE444286T1 AT05729779T AT05729779T ATE444286T1 AT E444286 T1 ATE444286 T1 AT E444286T1 AT 05729779 T AT05729779 T AT 05729779T AT 05729779 T AT05729779 T AT 05729779T AT E444286 T1 ATE444286 T1 AT E444286T1
Authority
AT
Austria
Prior art keywords
treatment
acid derivatives
prevention
pharmaceutical compositions
compounds
Prior art date
Application number
AT05729779T
Other languages
English (en)
Inventor
Marcello Allegretti
Riccardo Bertini
Maria Candida Cesta
Marco Mosca
Francesco Colotta
Original Assignee
Dompe Pha R Ma Spa Res & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Pha R Ma Spa Res & Mfg filed Critical Dompe Pha R Ma Spa Res & Mfg
Application granted granted Critical
Publication of ATE444286T1 publication Critical patent/ATE444286T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT05729779T 2004-03-23 2005-03-21 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung ATE444286T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101202 2004-03-23
PCT/EP2005/051302 WO2005090295A2 (en) 2004-03-23 2005-03-21 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
ATE444286T1 true ATE444286T1 (de) 2009-10-15

Family

ID=34970877

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05729779T ATE444286T1 (de) 2004-03-23 2005-03-21 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung

Country Status (21)

Country Link
US (2) US8039656B2 (de)
EP (1) EP1776336B1 (de)
JP (1) JP4871257B2 (de)
CN (2) CN101912382B (de)
AT (1) ATE444286T1 (de)
AU (1) AU2005223402B2 (de)
CA (1) CA2553705C (de)
CY (1) CY1109687T1 (de)
DE (1) DE602005016937D1 (de)
DK (1) DK1776336T3 (de)
ES (1) ES2333445T3 (de)
HK (2) HK1101392A1 (de)
HR (1) HRP20090681T1 (de)
ME (1) ME01763B (de)
NO (1) NO337685B1 (de)
PL (1) PL1776336T3 (de)
PT (1) PT1776336E (de)
RS (1) RS51109B (de)
RU (1) RU2375347C2 (de)
SI (1) SI1776336T1 (de)
WO (1) WO2005090295A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2458051C2 (ru) * 2005-11-24 2012-08-10 ДОМПЕ ФА.Р.МА С.п.А. (r)-арилалкиламинопроизводные и содержащие их фармацевтические композиции
DK2024329T3 (da) * 2006-05-18 2013-11-04 Dompe Spa (2r)-2-[(4-sulfonyl)aminophenyl]propanamider og farmaceutiske sammensætninger indeholdende dem
ES2394641T3 (es) * 2006-12-19 2013-02-04 Dompe' S.P.A. Ácidos 2-aril-2-fluoropropanoicos y derivados y composiciones farmacéuticas que los contienen
EP2166006A1 (de) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-Arylpropionsäuren und -Derivate und pharmazeutische Zusammensetzungen, die diese enthalten
EP2308485A1 (de) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamide zur Diabetesprävention
EP2308484A1 (de) * 2009-10-06 2011-04-13 Dompé S.p.a. Hemmer von CXCRL1/2 als Adjuvanzien bei der Transplantation von Langerhans-Zellen
EP2316820A1 (de) 2009-10-28 2011-05-04 Dompe S.p.A. Als Bradykinin-Rezeptorantagonisten nützliche 2-Arylpropionamid-Derivate und pharmazeutische Zusammensetzungen damit
MD480Z5 (ro) * 2011-07-07 2012-09-30 Эльвира АНДОН Metodă de tratament al colitei ulceroase nespecifice acute
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
EP3117835A1 (de) * 2015-07-14 2017-01-18 Dompé farmaceutici s.p.a. Il-8-inhibitoren zur verwendung bei der behandlung bestimmter urologischen erkrankungen
EP3192504A1 (de) 2016-01-15 2017-07-19 Dompé farmaceutici S.p.A. Il-8-inhibitoren zur verwendung bei der behandlung von durch chemotherapie ausgelöster peripherer neuropathie
AU2017207850B2 (en) * 2016-01-15 2022-06-30 Dompe' Farmaceutici S.P.A. IL-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
CN117503933A (zh) * 2016-10-03 2024-02-06 儿童医疗中心公司 糖尿病肾病的预防和治疗
EP3342407A1 (de) 2017-01-03 2018-07-04 Dompé farmaceutici S.p.A. Il-8-inihibitoren zur verwendung bei der behandlung von urologischen erkrankungen
EP3409277A1 (de) * 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8-inhibitoren zur verwendung bei der behandlung und/oder prävention von bakteriellen sekundärinfektionen
EP3476390A1 (de) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8-inhibitoren zur verwendung bei der behandlung von sarkomen
EP3498269A1 (de) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar-inhibitoren zur verwendung bei der behandlung von durch chemotherapie ausgelöstem iatrogenem schmerz
EP3868368A1 (de) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Inhibitor der aktivität von cxcl8 (interleukin-8) und corticosteroidkombination und pharmazeutische zusammensetzung und verwendung davon
EP3868369A1 (de) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8-inhibitor und pharmazeutische zusammensetzung davon zur verwendung in der behandlung von krebsbedingter ermüdung
WO2021191305A1 (en) 2020-03-26 2021-09-30 Dompe' Farmaceutici Spa Cxcl8 inhibitors for use in the treatment of covid-19
EP3884932A1 (de) 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8-inhibitoren zur verwendung bei der behandlung von covid-19
EP4008325A1 (de) 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8-inhibitoren zur verwendung bei der behandlung von covid-19
CA3196979A1 (en) * 2020-11-05 2022-05-12 Icahn School Of Medicine At Mount Sinai Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis
EP4052702A1 (de) 2021-03-04 2022-09-07 Dompé farmaceutici S.p.a. Cxcl8-inhibitor und dessen pharmazeutische zusammensetzung zur verwendung bei der behandlung von krampfanfällen
EP4397305A1 (de) 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Cxcl8-inhibitoren zur verwendung bei der behandlung von augenschleimhaut-pemphigoid und/oder mundschleimhaut-pemphigoid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE242208T1 (de) * 1997-01-29 2003-06-15 Pfizer Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
IT1317826B1 (it) * 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
ITMI20010395A1 (it) * 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
ITMI20012025A1 (it) * 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
ITMI20012434A1 (it) 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
WO2004069782A2 (en) * 2003-02-06 2004-08-19 Dompe' S.P.A. 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them
JP4795242B2 (ja) * 2003-09-25 2011-10-19 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ アミジン及びその誘導体並びにそれを含有する医薬組成物

Also Published As

Publication number Publication date
PT1776336E (pt) 2009-12-18
AU2005223402A1 (en) 2005-09-29
DE602005016937D1 (de) 2009-11-12
HK1148219A1 (en) 2011-09-02
US8293788B2 (en) 2012-10-23
PL1776336T3 (pl) 2010-06-30
NO337685B1 (no) 2016-06-06
CA2553705C (en) 2012-12-11
CA2553705A1 (en) 2005-09-29
CN1934077A (zh) 2007-03-21
RU2006137272A (ru) 2008-04-27
HRP20090681T1 (hr) 2010-02-28
EP1776336B1 (de) 2009-09-30
ES2333445T3 (es) 2010-02-22
ME01763B (de) 2010-10-31
WO2005090295A3 (en) 2005-10-27
EP1776336A2 (de) 2007-04-25
AU2005223402B2 (en) 2011-07-21
CN101912382B (zh) 2012-11-21
DK1776336T3 (da) 2010-01-18
JP2007530505A (ja) 2007-11-01
RS51109B (sr) 2010-10-31
US20090203740A1 (en) 2009-08-13
RU2375347C2 (ru) 2009-12-10
US8039656B2 (en) 2011-10-18
CN1934077B (zh) 2010-09-29
CN101912382A (zh) 2010-12-15
JP4871257B2 (ja) 2012-02-08
NO20064766L (no) 2006-10-20
WO2005090295A2 (en) 2005-09-29
CY1109687T1 (el) 2014-08-13
HK1101392A1 (en) 2007-10-18
SI1776336T1 (sl) 2010-01-29
US20120004264A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
ATE444286T1 (de) 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung
NO20054672L (no) Sulfonsyrer, derivater derav og farmasoytiske prepater omfattende slike forbindelser
Berkhout et al. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach
NO20054017L (no) 2-aryl-eddiksyrer, deres derivater og farmasoytisk sammensetninger som inneholder dem
NO20074641L (no) 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity
EA200701361A1 (ru) Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ
Le et al. Optimization of novel 1-methyl-1 h-pyrazole-5-carboxamides leads to high potency larval development inhibitors of the barber’s pole worm
Price et al. An orally available, brain-penetrant CAMKK2 inhibitor reduces food intake in rodent model
MXPA04004744A (es) Acidos 2-aril-propionicos y composiciones farmaceuticas que contienen a los mismo.
Gilbert et al. N-((8-Hydroxy-5-substituted-quinolin-7-yl)(phenyl) methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2)
Walker et al. Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase
George et al. Discovery of thieno [2, 3-c] pyridines as potent COT inhibitors
NO20080165L (no) Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister
EA200600879A1 (ru) Тетразольные производные и способы лечения расстройств, связанных с метаболизмом, с их помощью
DE602006007210D1 (de) Metaboliten aus 2-arylpropionsäure-derivaten und pharmazeutische zusammensetzungen damit
Miller et al. Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas—the effect of capping the distal basic piperidine nitrogen
Skotnicki et al. TNF-α converting enzyme (TACE) as a therapeutic target
Yokokawa et al. Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000–2008
Chen et al. Discovery of potent and specific CXCR3 antagonists
Laliberté et al. Discovery of a series of aryl-N-(3-(alkylamino)-5-(trifluoromethyl) phenyl) benzamides as TRPA1 antagonists
Sengupta et al. Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE
Wei et al. CCR5 receptor antagonists: Discovery and SAR study of guanylhydrazone derivatives
Shishido et al. Synthesis of benzamide derivatives as TRPV1 antagonists
Venkatraman et al. Influence of acid surrogates toward potency of VLA-4 antagonist
Vásquez Velásquez et al. 1-benzoyl-2-(2-nitrophenyl)-1H-benzimidazole derivatives: A novel approach to the development of new HIV-1 reverse transcriptase inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1776336

Country of ref document: EP

EEIH Change in the person of patent owner